CRISPR/Cas9-based gene therapy (Exonics Therapeutics)

N/A

Report date: 2025/01/26 18:07:54

Base Information

Drug NameCRISPR/Cas9-based gene therapy (Exonics Therapeutics)

Drug Alias Nameadeno-associated viruses encoding the gene-editing enzyme CRISPR/Cas9 therapy (Exonics Therapeutics)AAV gene therapy (Exonics Therapeutics)

ClassificationBiologics

Mechanisms of ActionDystrophin gene transference

TargetsDystrophin

Therapy Area/IndicationsMuscular Dystrophy, Duchenne

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesExonics Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesExonics Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsMuscular Dystrophy, Duchenne

Inactive IndicationsN/A

Other Information

ATC CodeN/A